24

Doctors in the United States successfully treated a baby named KJ with a rare genetic condition using CRISPR gene-editing technology. KJ suffers from CPS1 deficiency, a disorder affecting roughly one in a million newborns. The disease causes toxic ammonia to build up in the blood, which can lead to severe brain damage or death if left untreated.

At six months old, KJ began receiving personalized CRISPR therapy at the Children’s Hospital of Philadelphia. This treatment targeted the faulty gene in his liver, aiming to reduce dangerous ammonia levels and ease symptoms.

What is CPS1 Deficiency?

CPS1 deficiency prevents the body from processing ammonia, a toxic waste product. Without treatment, babies suffer from vomiting, seizures, brain swelling, and often die within weeks. Traditional care includes strict low-protein diets and eventual liver transplants to manage the condition.

KJ’s new therapy corrects the enzyme defect responsible for the disease. Dr. Rebecca Ahrens-Nicklas, who led the procedure, said the results have exceeded expectations so far.

How CRISPR Therapy Works

CRISPR is a gene-editing tool that allows doctors to target and fix specific DNA sequences. In KJ’s case, the treatment edited the faulty gene in his liver cells, enabling the body to naturally repair the enzyme deficiency.

Doctors believe this approach could benefit many patients with rare single-gene disorders, especially as techniques become easier to customize.

“We are hopeful that personalized CRISPR therapies will become more common for treating genetic diseases,” Dr. Ahrens-Nicklas said. She added that the method shows promise for high accuracy and fewer side effects.

The Future of Gene Editing for Rare Diseases

This breakthrough could pave the way for more clinical trials focused on rare disorders with known genetic causes. Experts emphasize CRISPR’s potential to treat conditions previously considered untreatable.

However, researchers warn that delivering gene edits to organs beyond the liver remains complex. Current technology faces challenges reaching other tissues safely and effectively.

Challenges: Cost and Complexity

Each personalized CRISPR treatment currently costs over €700,000, a price comparable to a liver transplant. Long-term side effects remain unknown, as safety studies continue.

Geneticist Dr. Alena Pance explained that CRISPR works best for diseases caused by single genetic mutations. She noted that many conditions involve multiple gene changes, which might require broader therapies.

“CRISPR is a powerful tool, but we still need to develop strategies for more complex genetic disorders,” Dr. Pance said.

Despite hurdles, the medical community is optimistic about CRISPR’s role in fighting rare, life-threatening diseases.

Doctors will closely monitor KJ for the rest of his life to ensure the treatment’s lasting success. The team hopes this case will encourage further investment and research into gene-editing therapies.